

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of: Boggs et al.

US National Serial No: 10/535,228

Filed:

Title: Farnesoid X Receptor Agonists

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 C.F.R. § 1.821-1.825

Commissioner for Patents
Washington, D.C. 20231


Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821 (g), does not include new matter;
2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821 (c) and (e), respectively, are the same; and
3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted

7 Feb 2006
Date


Lorie Ann Morgan
Attorney of Record, Reg. No. 38,181

GlaxoSmithKline
Corporate Intellectual Property Department
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398 US
Phone: 919-483-8222
Facsimile: 919-483-7988